Abstract: Nanoparticles are used in medicine to deliver drugs, for imaging, for vaccination and for local heating of tissue (tumor thermotherapy). If malignant tissue shall be addressed, it is of prime importance to direct the nanoparticles to their target. This can be accomplished by making use of physical effects (e.g., the EPR effect: enhanced permeation and retention) or by chemical modification of the nanoparticles to specifically recognize cells or tissues. The efficiency of the targeting can be assessed by in vitro cell culture experiments and also in vivo in animal experiments. As they are closest to the practical clinical application, in vivo imaging methods are particularly suitable to monitor the targeting. In general, a limited colloid-chemical stability of the nanoparticles in a biological environment and the formation of a protein corona around the nanoparticle may constrain their targeting ability. The current state of such targeting strategies is reviewed and discussed.
Introduction
Nanotechnology denotes the creation and application of matter in the size range of 1-100 nm. The application of nanotechnology to medicine, typically denoted as nanomedicine, deals with the use of precisely engineered materials at this length scale to develop novel therapeutic nanocarriers [1] [2] [3] [4] [5] . The wide variety of nanoparticles, coupled with tuneable surface properties and the possibility to load them with different compounds or drugs, makes them an excellent platform for a broad range of biological and biomedical applications. The conjugation of different molecules to the nanoparticles can improve their properties and (in principle) allows a targeted delivery of these nanoparticles to various cell types and tissues for imaging, gene delivery, drug delivery and other therapeutic and diagnostic applications.
The historical development of such targeting approaches can be traced back to the work of Ehrlich and his concept of "Magic Bullets", and also to the work of Speiser who first focused on the development of nanoparticles for vaccination in the 1960s and 1970s [6] . With the rapid development of our knowledge to prepare nanomaterials in the following decades, it is now possible to combine specialized delivery systems and targeting approaches to develop selective and effective therapeutic and diagnostic tools to improve the outcome of important diseases, including cancer diagnosis and therapy [5, 7] . Ideally, a targeted drug delivery would avoid side effects in the body and lead to pharmacologically active compounds directed to the cells or tissues where they can exert their therapeutic action. The typical systems for drug delivery in cancer therapy are nanoparticles, liposomes, polymeric micelles, dendrimers and polymer-drug conjugates [8, 9] . However, the biological activity of such a system including its targeting ability is determined by size, shape, surface chemistry and surface coatings [10] . Here, we review the state of the art of the current achievements in nanoparticles for targeting, especially for drug delivery and tumor therapy.
kinetics, and chemical composition [5, 11] . To understand these factors, both experimental (i.e., analytical) as well as simulation techniques are applied [12, 13] . Depending on the envisioned application, nanoparticles are adapted to deliver different kinds of therapeutic agents like small drug molecules [14, 15] and biomolecules (peptides, proteins, nucleic acids) [16] [17] [18] . Furthermore, metallic nanoparticles (often gold) [19] [20] [21] [22] [23] [24] [25] [26] [27] and magnetic nanoparticles (often magnetite, Fe 3 O 4 , or maghemite, Fe 2 O 3 ) [28] [29] [30] are used for tumor targeting, followed by local heat application ("tumor thermotherapy"), [31, 32] and also for imaging in the body. Table 1 and Figure 1 list some typically applied nanocarriers.
In the following, we will restrict our discussion to nanoparticles. Many characteristics and different components of the particulate system may affect the performance of the nanoparticle to achieve the required goal. Particle size and size distribution are the most important characteristics of nanoparticulate systems [35] . Important in vivo functions of particles depend on the particle size, the agglomeration tendency, the circulation time in the body, the immunogenicity, the cellular uptake, the intracellular trafficking, the degradation by cells or physicochemical dissolution, the flow properties in the bloodstream and the clearance from the blood [11, 36] . Nanoparticles with a size smaller than 20-30 nm are rapidly cleared by renal excretion, whereas bigger nanoparticles up to the micrometer size are more efficiently taken up by the mononuclear phagocytic system [37] . It is important to note that nanoparticles with a size of 150-300 nm mainly end up in the liver and in the spleen, whereas particles of 30-150 nm are found in bone marrow, heart, kidney and stomach. It has also been reported that nanoparticles should be smaller than 150 nm to cross the endothelial barrier [38] . It must be stressed that nanoparticles may agglomerate when brought from water into biological media, [39] and therefore the particle size data which were obtained in water are not necessarily representative for the actual particle size in vivo.
Besides the particle size, the surface properties are probably the most deciding factor for nanoparticle behaviour and their interaction with proteins and cells [40, 41] . The colloidal stability of nanoparticles directly depends on the surface characteristics (charge, hydrophobicity, functional groups). It can be estimated by the zeta potential in the case of electrostatic stabilization: Nanoparticles with a zeta potential above (+/-) 30 mV have been shown to be stable in suspension, as the surface charge prevents aggregation of the particles [36] . Furthermore, the surface charge of nanoparticles regulates their biodistribution [42] . Uncharged nanoparticle surfaces tend to bind less protein than their negatively or positively charged equivalents [43, 44] . During the circulation time in a biological Table 1 Some nanocarriers for targeting approaches [8, 33, 34] .
Nanocarrier Properties
Nanoparticles Nanoparticles are solid and usually spherical structures with a size between 2 and 100 nm, sometimes of a multi-shell nature. They may also be non-spherical.
Micelles
Micelles are typically spherical objects with a hydrophobic core and a hydrophilic corona, consisting of surfactants or polyelectrolytes. These systems are of a dynamic nature and usually have a diameter below 20 nm. Liposomes Liposomes are spherical vesicles formed by one or more (phospho-)lipid bilayers. They are colloidal systems composed of amphiphilic phospholipids that undergo self-assembly into bilayers that form the spherical vesicles. Dendrimers These carriers are highly branched organic macromolecules with controlled three-dimensional structure. Polymers grow from a central core by a series of polymerisation reactions. Polymer-drug conjugates
Conjugates are macromolecules consisting of a polymer backbone to which drugs are conjugated by an organic linker. medium, nanoparticles will interact with biomolecules like proteins, nucleic acids, lipids and biological metabolites due to their small size and their large specific surface area. The proteins can adsorb on the nanoparticle surface and form a protein-corona [45] [46] [47] . The protein binding in part depends on the particle size [44] . For example, Deng et al. have demonstrated a higher fibrinogen binding affinity to 12 nm-sized negatively charged polyacrylic acid-coated gold nanoparticles than to 7 nm nanoparticles [48] . The binding capability of the protein lysozyme was investigated with silica nanoparticles. Some 100 nmsilica nanoparticles were capable to induce a greater loss of structure and function for the studied protein in comparison to 4 nm-sized nanoparticles [49] . Another stabilization method is steric stabilization, typically by attaching polymers or similar components to the nanoparticle surface. A manipulation of the surface hydrophobicity can also change the behavior of nanoparticles in live systems. Particles with a hydrophilic surfaces can become more hydrophobic in circulation by adsorption of immunoglobulin G (IgG) whereas hydrophobic particles can be directly taken up by macrophages without opsonization [16] . A frequently used approach to provide a hydrophilic surface and to protect the nanoparticles from the adsorption of proteins and immune recognition is a functionalization of nanoparticles with poly(ethylene glycol) (PEG), so-called "PEGylation". This widely used method to protect nanocarriers from the reticulo-endothelial system consists of coating the surface of the particles with polyethylene glycol (PEG) [50, 51] . This leads to a "stealth character" of the nanoparticle, which prevents it from being recognized by immune cells. For the coating procedure three factors are important: The molecular weight of the PEG chain (i.e., the polymer chain length), the surface chain density and the conformation of the polymer chain [8] . The coating of nanoparticles with PEG can prolong the particle life time in the body and affect other biological processes, including endocytosis, protein adsorption and cell adhesion [11, 52] . Larger nanoparticles in the 50-100 nm size are mostly coated with shorter chains of PEG because a further increase in hydrodynamic radius may decrease the circulation time. In magnetic resonance imaging, one of the first nanoparticulate systems involved PEGylated superparamagnetic iron oxide nanoparticles with a long blood circulation time, as these coatings on the nanoparticles are biocompatible, non-immunogenic, and non-antigenic [53, 54] .
Targeting molecules
Targeting strategies evolved with the development of synthetically applicable antibodies in the late 1970s and subsequently led to the development of targeting nanoparticles and immunoliposomes [55] . The conjugation of different molecules to the nanoparticles permitted their use in a wider range of application fields and equipped them with new properties, aimed at a specific recognition of cell types (like tumor cells) or tissues. The commonly used classification of targeting moieties is shown in Table 2 [56] [57] [58] [59] [60] . Table 2 Classification of targeting molecules used for nanoparticle functionalization.
Targeting molecule Definition Properties
Antibodies (proteins) Immunoglobulines and anti-bodies are a group of glycoproteins that are a part of the specific defence mechanism in the body. Antibodies can target a specific receptor, interfere with signal-transduction pathways, and regulate proto-oncogenes involved in cancer cell proliferation [8] . Examples: Antibodies, antibody fragments, transferrin [61] , and lectin [62] . Aptamers Aptamers are single stranded nucleic acids, i.e. DNA, RNA, or synthetic oligonucleotides with well-defined three-dimensional structures [43] . Aptamers can recognize a wide variety of molecules (proteins, phospholipids, sugars, and nucleic acids) with high affinity and specificity [59] . Examples: ssDNA and ssRNA [63] [64] [65] [66] [67] . Peptides Natural or synthetic short polymer chain compounds, containing a limited number of amino acids. Peptides can bind very specifically with high affinity to their cognate receptors, often with affinities comparable to those of full-length antibodies [68] . Examples: RGD, LHRD, and antigenic peptides [69, 70] A wide spectrum of chemical approaches has been developed to conjugate targeting moieties to the surface of nanoparticles [74, 78] . The conjugation can be achieved either by chemisorption of the biomolecule to the nanoparticle surface or by the use of bifunctional linkers. Chemisorption of biomolecules (e.g., antibodies, proteins, peptide) onto the nanoparticle surface (e.g., gold or gold-containing nanoparticles, quantum dots like ZnS, CdS, CdSe/ZnS) can be enhanced by cysteine residues that are present in the protein surface or chemically by using 2-iminothiolane (Traut's reagent) [79, 80] . Bifunctionals linkers provide a versatile means of nanoparticle conjugation with biomolecules [81] [82] [83] [84] . Biomolecules are often covalently conjugated to the surface-modified nanoparticles by traditional coupling strategies such as carbodiimide-mediated amidation and esterification [79, 85] .
The primary goal of targeted ligand conjugation is to bind a targeting moiety without losing its functionality after attachment to the nanoparticle. Possible applications of targeting nanoparticles are the selective delivery of a therapeutic agent, such as a drug, a gene or even heat to cause the death of malignant cells or the up-or downregulation of a specific protein, ideally all without affecting of the healthy tissue. Figure 2 schematically shows a functionalized nanoparticle for addressing of cells.
In the last decades, several types of advanced functionalized nanoparticles have been synthesized and proposed for use as contrast agents for diagnostics and imaging, for drug delivery, and for tumor thermotherapy. The mechanisms of cellular uptake [86] [87] [88] [89] [90] [91] [92] and intracellular localization [93, 94] of nanoparticles were investigated in order to interpret data from in vitro studies and to improve the in vivo use of the particles [95] .
Principles of tumor targeting by nanoparticles
Various concepts have been developed for nanomedicine-based drug targeting to tumors, including passive and active targeting to cancer cells [7, 96] . Passive targeting, also known as physical targeting, is based on the accumulation of drugs or drug-loaded particles in the areas around a tumor with leaky vasculature (Figure 3 ) [97] . This leakiness is due to the rapid proliferation of endothelial cells and a lower number of pericytes, resulting in pores in the tumor vasculature ranging from 100 to several 100 nanometers in diameter, much larger than pores in normal blood vessels of 5-10 nm [34, 37] . The increased vascular permeability coupled with a dysfunctional lymphatic drainage system (preventing a rapid removal of the nanoparticles) in a rapidly growing tumor leads to the so-called "enhanced permeation and retention (EPR)" effect [98, 99] . The exploitation of the EPR effect is still a major objective in cancer-targeting drug design [8, 96] .
As opposed to passive targeting, "active targeting" relies on targeting ligands which specifically bind to receptor structures at the target site [8] . Active drug targeting is generally implemented to improve target cell recognition and uptake by target cells. Tumor cells express many molecules on their surface that distinguish them from normal cells. Antigens that are expressed on tumor cells but not on normal cells are called "tumorspecific antigens"; some of these antigens are unique to individual tumor types, whereas others are shared among tumors of the same type [96] . Thus, the conjugation of nanoparticles with specific ligands can improve the selective affinity for recognizing and interacting with a specific cell, tissue or organ in the body by means of receptor-targeted ligands [99] (Figure 4 ). Note that there is no general "tumor-marker" which is common to and selective for all kinds of tumor cells.
Kumar et al. studied the uptake of transferrin-, anticlaudin 4-and anti-mesothelin-coated silica nanoparticles (20 nm) by pancreatic cancer cell lines. Bioconjugated nanoparticles showed a higher uptake ( > 90%) in comparison to the nonconjugated ones (56%) [100] . Farokhzad and co-workers showed a 77-fold increase of aptamercoated PEG-ylated poly(lactic acid) nanoparticles in intracellular uptake by prostate cancer cells in vitro compared Figure 3 Passive targeting of nanoparticles to solid tumor due to the EPR-effect. Nanoparticles can enter a tumor through a blood vessel with a more porous wall than a that of a normal blood vessel. Furthermore, the absence of a lymphatic system leads to an accumulation of the nanoparticles in the tumor. with non-targeted nanoparticles [101] . Liong et al. demonstrated a more than 2-fold higher cellular uptake of folate-coated mesostructured silica spheres doped with superparamagnetic iron oxide nanoparticles (100-200 nm) by the human pancreatic cancer cell line (PANC-1) in comparison to nonconjugated nanoparticles [102] . Han et al. showed that Arg-Gly-Asp (RGD) peptide-coated chitosan nanoparticles loaded with siRNA (200 nm) significantly enhanced the antitumor therapeutic efficacy compared to a nontargeted delivery system in preclinical ovarian cancer models [70] . We have demonstrated that calcium phosphate nanoparticles, conjugated with antibodies, can selectively target dendritic cells out of a mixed cell population of spleen cells [103] . Bandyopadhyay et al. showed by in vivo experiments that the density of the anti-DEC-205 antibody on the surface of ovalbumincontaining poly(lactide-co-glycolic acid) (PLGA) nanoparticles may modulate the cytokine response and the expression of scavenger receptors. They also found that an increased density of anti-DEC-205 on the surface of nanoparticles correlated with higher cross-linking of its receptor and resulted in a increased expression of CD36 [104] , Zhu et al. investigated paclitaxel-loaded poly(ε-caprolactone)-b-poly(N-vinylpyrrolidone) (PCL-b-PVP) copolymers with different poly(N-vinylpyrrolidone) (PVP) block length conjugated with the tumor-adressing peptide iRGD. They showed that iRGD on the PCL-b-PVP nanoparticle surface facilitated the nanoparticles to accumulate at the tumor site and enhanced their penetration into tumor tissue, both of which improved the efficacy of paclitaxelloaded nanoparticles in constraining tumor growth and prolonging the life expectancy of H22 tumor-bearing mice [105] . A targeted delivery of nanoparticles in the central nervous system has also been investigated by number of research groups [106] [107] [108] [109] . For example, Tian et al. demonstrated the improved delivery of SynB peptideconjugated PEGylated gelatin-siloxane (GS) nanoparticles to the brain. The modification of the nanoparticles with the SynB peptide not only improved the ability of PEG-GS nanoparticles to evade capture in the reticuloendothelial system but also enhanced their efficiency in crossing the blood-brain barrier [110] .
Despite these successes, the results of in vivo studies are not always consistent, and the advantage over passive targeting is still under debate [52] . The active targeting of nanoparticles can be limited by a number of anatomical and physiological barriers that need to be overcome before targeted nanoparticles can bind to (and enter) cancer cells [7] . The most preventing factor of active targeting after interactions between nanosized particles and biological environment is probably the protein corona. The targeting ability of functionalized nanoparticles may be lost after the adsorption of proteins onto the nanoparticle surface because the targeting moieties are "buried" below the protein corona [45] [46] [47] .
Ideally, the nanoparticles should selectively accumulate at the tumor site after systemic delivery. The targeting ability of nanoparticles can be analyzed in the cell culture and in vivo, typically by making them fluorescent. Multifunctional nanoparticles for simultaneous treatment and near infrared (NIR) fluorescence imaging in vivo can be prepared due to the very low tissue autofluorescence and high tissue penetration depth in the NIR spectral window between 700 and 1000 nm [111] [112] [113] [114] . A variety of targeted NIR dye-labeled nanoparticles has been developed to study their biodistribution, clearance, and biocompatibility for in vivo biomedical applications. For example, Kumar et al. investigated DY-776-conjugated silica nanoparticles for in vivo bioimaging, biodistribution, clearance and toxicity analyses [115] . Wang et al. showed that NIR-797-labelled piperlongumine-(PLGMA) loaded poly(ethylene glycol) and poly(dehydroabietic ethyl methacrylate) (PEG-b-PDAEMA) nanoparticles effectively targeted a tumor site by the EPR-effect in H22 tumor-bearing mice [116] . Near infrared fluorescence (NIRF) imaging has also been applied for the labelling of magnetic iron nanoparticles. Hou et al. used m-2, 3-dimercaptosuccinic acid (DMSA)-coated iron oxide nanoparticles, covalently modified with IRDy800CW for cell labeling and tracing the in vivo biodistribution [117] . By such studies, the targeting ability can be verified under realistic in vivo conditions.
Conclusions
Nanoparticles can be engineered as devices for an effective and targeted delivery of drugs and imaging labels able to overcome biological barriers, to deliver active compounds (e.g., drugs, peptides, polynucleotides) and to preferentially target sites of disease. However, despite these potential advantages, only a relatively small number of nanoparticle-based medicines has been approved for clinical use [7, 96] . Cell culture studies with just one cell line are hardly suitable to demonstrate a successful targeting. At least co-cultures with two or more cell types should be applied. Even then, there remains the question whether a successful targeting in vitro can be easily transposed to the situation in vivo where many cell and tissue types are present, where clearing mechanisms must be avoided, where the nanoparticles have to find their way by diffusion or with the bloodstream to their target, and where many different biomolecules may passivate the nanoparticle surface. A suitable instrument to study such effects under realistic conditions is in vivo imaging of nanoparticles which have been labelled with near-infrared dyes.
Some particularly important properties of nanoparticles shall be summarized in the following. They should be larger than about 20 nm (to avoid the filtration by the kidneys) and smaller than about 150 nm (to avoid the filtration by the liver). The charge of the particles should be neutral or anionic for efficient evasion of renal elimination. The nanoparticles must be hidden from the reticuloendothelial system, which eliminates any foreign material through opsonisation, followed by phagocytosis.
Finally, it should be noted that cellular targeting is not the same as cellular uptake. An accumulation of nanoparticles at the surface of a cell is a necessary precondition for the latter uptake, but it should be kept in mind that the cellular uptake of nanoparticles follows its own rules and depends, inter alia on particle size, charge and surface functionalities [92, 118] . This may be important if a drug should exert its action inside a cell.
